EcoDrugPlus

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSECRG00000004132
Gene Symbol: FRK
3 Cross references
217 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSECRG00000013168
Gene Symbol: GLA
3 Cross references
197 Possible Orthologues:

Galectin-3-Like

Ensembl ID : ENSECRG00000020822
Gene Symbol: LOC114666537
3 Cross references
220 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSECRG00000015092
Gene Symbol: GABBR2
1 Cross references
208 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha1 Subunit

Ensembl ID : ENSECRG00000013884
Gene Symbol: GABRA1
3 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha2 Subunit

Ensembl ID : ENSECRG00000002665
Gene Symbol: GABRA2
2 Cross references
203 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Beta2 Subunit

Ensembl ID : ENSECRG00000013694
Gene Symbol: GABRB2
3 Cross references
255 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSECRG00000015831
Gene Symbol: GABRA3
3 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4

Ensembl ID : ENSECRG00000002606
Gene Symbol: GABRA4
1 Cross references
128 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSECRG00000014988
Gene Symbol: GABRA5
3 Cross references
266 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSECRG00000015165
Gene Symbol: GABRB3
1 Cross references
256 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSECRG00000006467
Gene Symbol: GABRD
3 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).